Navigation Links
Roxane Laboratories, Inc. Announces the Launch of Balsalazide Disodium Capsules, 750mg
Date:1/3/2008

COLUMBUS, Ohio, Jan. 2 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Balsalazide Disodium Capsules, 750mg by the U.S. Food and Drug Administration. The product is available in bottles of 280 capsules for immediate shipment to wholesalers and pharmacies nationwide.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070410/CLTU122LOGO )

Roxane Laboratories' Balsalazide Disodium Capsules, 750mg are AB rated to COLAZAL(R) (balsalazide disodium). Annual sales of Balsalazide Disodium Capsules, 750mg are approximately $132 Million(1).

Full prescribing information for Balsalazide Disodium Capsules, 750mg is available on the Roxane Laboratories website at http://www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 75 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled release tablets; nasal sprays, cytotoxics and CII narcotics. Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2006, Boehringer Ingelheim posted net sales of US $13.3 billion (10.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information on Boehringer Ingelheim, please visit http://us.boehringer-ingelheim.com.

(1) IMS MAT dollar sales ending 06/2007

COLAZAL(R) is a registered trademark of SALIX Pharmaceuticals, Inc.


'/>"/>
SOURCE Roxane Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
3. Bond Laboratories, Inc. Announces 2-for-1 Forward Split
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
5. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
6. Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
8. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... 2016 , ... Christie Medical Holdings, Inc. presented the Baylor ... Vision vein finder for the nursing school simulation lab. This donation ... blood, combining technology with traditional technique. , “VeinViewer is a wonderful new addition ...
(Date:2/12/2016)... ... February 12, 2016 , ... According to an article ... account for a significant portion of hernia repairs throughout the United States. Commenting on ... Hernia Center notes that this trend has not only been expected, but it seems ...
(Date:2/12/2016)... ... 12, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... at its 10th anniversary Fashion Luncheon on Monday, February 8, 2016. The special ...
(Date:2/12/2016)... Los Angeles, CA (PRWEB) , ... February 12, 2016 , ... ... be. With a hectic schedule, a demanding job, and no time to decompress, Rabinowitz ... there, she dedicated herself to meditation for its impact on her life, implementing a ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Service (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) into Cielo®, ... to offer real-time business intelligence (BI) to their small and medium business (SMB) ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Mich. , Feb. 12, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO ) is pleased ... Pharmaceutical Account Management and Payor Strategies effective Jan. 23, 2016. ... ... ... Diplomat Specialty Pharmacy ...
(Date:2/12/2016)... - Demers Ambulances announces its first delivery in the state of ... Emergency Medical Services (EMS) consisting of four vehicles: ... Quality Emergency Vehicles in Lecanto, FL , ... is the latest in Demers, ongoing expansion of sales.  ... --> Benoit LaFortune , Executive Vice President at ...
(Date:2/12/2016)... --  HeartWare International, Inc . (NASDAQ: HTWR ) ... its financial results for the three and 12 months ... at 8:00 a.m. ET.  The company plans to release ... webcast.  On the conference call and webcast, management will ... quarter and business outlook.   --> ...
Breaking Medicine Technology: